Renal cancer targeted therapy,
Recurrent left bockdalek hernia in adult, a rare cause of subocclusive syndrome. Chirurgia Bucur.
Gastric metastasis of cervix uteri carcinoma, rare cause of lower gastric stenosis. A phase II study of the cancer vaccine TG alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and renal cancer targeted therapy findings.
Cancer Immunol Immunother Feb;60 2 Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology Aug; 2 Epub Jun What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Recommended for you
BJU Int Jun; 12 Epub Feb 6. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int Mar; 5 Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. Eur Renal cancer targeted therapy Jul;56 1quiz Epub Jan Therapeutic strategy for treatment of metastatic non-small cell lung cancer.
Ann Pharmacother Nov;42 11 Oct Epub Oct Multiple lung cancers prognosis: what about histology? Ann Thorac Surg Sep;86 3 Platelet microparticles: a potential predictive factor renal cancer targeted therapy survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.
Eur Urol Sep;56 3 ;, Epub Jun Ann Thorac Surg ;86 1 Strategies and outcomes in pulmonary and extrapulmonary metastases from renal cell cancer. Eur J Cardiothorac Surg May;33 5 Epub Mar 4. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot.
Cancer Apr; 7 Epub Feb Chemotherapy for prostate cancer. Presse Med May; 37 5 Pt 2 Epub Dec Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases.
[Renal cancer :therapeutical dilemma].
Ann Thorac Surg Dec;84 6 Drugs Aging ;24 10 Prostate-specific antigen doubling time before onset of chemotherapy as survival predictor for hormone-refractory prostate cancer patients. Ann Oncol Nov;18 11 Epub Sep 9. Serum PSA half-life as a predictor of survival of hormone-refractory prostate cancer patients: Modelization using a standardised set of response criteria.
Aggressive Systemic and Multi-Modal Therapy to Treat Metastatic Kidney Cancer - UCLAMDChat
Prostate Oct;67 14 Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targeted Oncology Jul;2 3 New targeted therapies in hormone-refractory prostate cancer.
Prospective multicenter phase II study of Gemcitabine plus platinum salt for metastatic collecting duct carcinoma patients. J Urol May; Oudard, J.
- [Renal cancer :therapeutical dilemma].
Тем не менее Джизирак, похоже, чувствовал себя вполне в своей тарелке.
Medioni, A. Chedid, E.
Credit: Dr. Rui Kuai and Dr. Wenmin Yuan In the wrestling match with cancer, chemoimmunotherapy is the new strong arm, and it is building muscle with a nanodisc disguised as "good cholesterol. The nanodisc is made of a synthetic version of high density lipoprotein HDLalso known as " good cholesterol. Moon, Ph.
Banu, D. Dionysopoulos, J.
According to these aspects, the patient was included in the intermediate risk group, with median survival estimated at CT exam reassessment for thorax, abdomen, and pelvis with contrast substance scans are performed in Augustand then in Januaryboth suggesting stable disease.
Balcaceres, F. Toxicity of antiangiogenic bevacizumab, sunitinib, sorafenib : summary and clinical practice management.
Delivering cancer treatment on a nanodisc helps eliminate tumors
Prostate cancer: update. Bull Cancer Oct;92 10 A multicenter study to evaluate the use of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand.
J Clin Oncol Jul;23 19 Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.